Inactive Instrument

Highlights Medgenics, Inc. Nyse

Equities

US58436Q2030

End-of-day quote Nyse Other stock markets
- ^USD	-

2020	Aevi Genomic Medicine, LLC(NasdaqGM:GNMX) dropped from S&P TMI Index	CI
2020	Aevi Genomic Medicine, Inc. Announces Resignation of Directors	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Cerecor Inc. completed the acquisition of Aevi Genomic Medicine, Inc..	03/20/03	CI
Aevi Genomic Medicine, Inc. Doses the First Patient with AEVI-002 in A Phase Ib Clinical Trial	23/19/23	CI
Aevi Genomic Medicine, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	14/19/14	CI
Cerecor Inc. entered into a definitive merger agreement to acquire Aevi Genomic Medicine, Inc. for $15.6 million.	14/19/14	CI
Aevi Genomic Medicine, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	14/19/14	CI
Aevi Genomic Medicine, Inc. Obtains License for Medi2338, Phase 2-Ready Fully Human Monoclonal Antibody That Targets Interleukin 18 (IL-18)	07/19/07	CI
Aevi Genomic Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	14/19/14	CI
Aevi Genomic Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	30/19/30	CI
Aevi Genomic Medicine Announces Top-Line Results from Placebo-Controlled ASCEND Trial of AEVI-001 in Children with ADHD	03/19/03	CI
Aevi Genomic Medicine, Inc. Reports Consolidated Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	01/18/01	CI
Aevi Genomic Medicine, Inc. Announces Completion of Enrollment for Part B of the Ascend Trial	15/18/15	CI
Aevi Genomic Medicine, Inc. Announces Completion of Enrollment in Part A of Phase 2 ASCEND Trial in ADHD	14/18/14	CI
Aevi Genomic Medicine, Inc. Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2018	02/18/02	CI
Aevi Genomic Medicine, Inc. Announces Novel Co-crystal Version of AEVI-001	19/18/19	CI
Aevi Genomic Medicine Provides Update on Sample Size Re-Estimation for Phase 2 ASCEND Trial in ADHD	12/18/12	CI
Aevi Genomic Medicine, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018	15/18/15	CI
Aevi Genomic Medicine, Inc. Reports Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2017	13/18/13	CI
Aevi Genomic Medicine, Inc. Expands Collaboration with Kyowa Hakko Kirin Co., Ltd	07/18/07	CI
Aevi Genomic Medicine, Inc. Reports Consolidated Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	02/17/02	CI
Aevi Genomic Medicine, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017	10/17/10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Medgenics, Inc. Nyse

Equities

US58436Q2030

Highlights

Filters